vorinostat has been researched along with Thrombosis in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral vorinostat 200 mg was administered twice daily on days 1-14 along with 375 mg/m(2) of intravenous rituximab on day 1 of a 21-day cycle, continuing until disease progression or unacceptable toxicity." | 2.80 | A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. ( Chen, R; Forman, SJ; Frankel, P; Htut, M; Kirschbaum, M; Mott, M; Nademanee, A; Nathwani, N; Popplewell, L; Rotter, A; Ruel, N; Siddiqi, T; Thomas, SH, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, R | 1 |
| Frankel, P | 1 |
| Popplewell, L | 1 |
| Siddiqi, T | 1 |
| Ruel, N | 1 |
| Rotter, A | 1 |
| Thomas, SH | 1 |
| Mott, M | 1 |
| Nathwani, N | 1 |
| Htut, M | 1 |
| Nademanee, A | 1 |
| Forman, SJ | 1 |
| Kirschbaum, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma[NCT00720876] | Phase 2 | 30 participants (Actual) | Interventional | 2008-07-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response was assessed according to the 2007 Cheson criteria using CT scans or PET: Complete Response (CR), Disappearance of all evidence of disease; Partial Response (PR), >=50% decrease in the Sum of the Product of Diameters (SPD) of up to 6 largest dominant masses and no increase in the size of other nodes; Overall Response (OR) = CR + PR. (NCT00720876)
Timeframe: After every 3 cycles, up to 1 year after the start of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Vorinostat and Rituximab | 46 |
ProgressionRelapse is defined using the 2007 Cheson criteria, as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy; or at least a 50% increase for nadir in the SPD of any previously involved nodes; or at least a 50% increase in the longest diameter of any singe previously identified node more than 1 cm in its short axis. Estimated using the product-limit method of Kaplan and Meier. (NCT00720876)
Timeframe: Until disease progress
elapse, up to 1 year after the start of treatment
| Intervention | Months (Median) |
|---|---|
| Vorinostat and Rituximab | 29.2 |
Grade 3 & 4 toxicities at least possible related to study drugs during any cycle of treatment. Toxicity graded according to Common Terminology Criteria for Adverse Events version 3.0. (NCT00720876)
Timeframe: 3 weeks after the stop of treatment
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutrophil count decreased | Platelet count decreased | Hemoglobin decreased | Lymphocyte count decreased | Hypotension | Chills | Fatigue | Dehydration | Diarrhea | Kidney infection | Pneumonia | Sepsis | Urinary tract infection | Localized edema | Alanine aminotransferase increased | Aspartate aminotransferase increased | Blood glucose increased | Serum phosphate decreased | Serum potassium decreased | Muscle weakness | Syncope | Hypoxia | Pneumonitis | Thrombosis | Vascular access complication | |
| Vorinostat and Rituximab | 3 | 5 | 1 | 7 | 2 | 1 | 9 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 4 | 1 |
1 trial available for vorinostat and Thrombosis
| Article | Year |
|---|---|
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2015 |